Immix Biopharma, Inc. IMMX
Immix Biopharma, Inc. (Nasdaq: IMMX) is a hematology drug developer. Its lead program, NXC-201 (CAR-T), is in Phase 2 for relapsed/refractory AL amyloidosis. Its next catalyst on record is NXC-201: NEXICART-2 final readout followed by BLA submission (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NXC-201 — NEXICART-2 final readout followed by BLA submission (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NXC-201 (NEXICART-2, US Phase 1b/2) | relapsed/refractory AL amyloidosis | cell therapy | Phase 2 |
| NXC-201 (NEXICART-1, ex-US Phase 1b/2a) | relapsed/refractory AL amyloidosis | cell therapy | Phase 2 |
| NXC-201 newly diagnosed AL amyloidosis (planned randomized Phase 3) | newly diagnosed AL amyloidosis | cell therapy | Pre-clinical |
| Other NXC-201 indications and preclinical candidates | — | cell therapy | Pre-clinical |
Recent results and decisions
- Sep 29, 2026n/a Immix Biopharma priced underwritten public offering of 11,363,637 shares of common stock at $11.00 per share for expected net proceeds of approximately $117.1 million.
The Company estimates that the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions, and estimated offering expenses, are expected to be approximately $117.1 million.
Filing - Mar 30, 2026completed enrollment Enrollment completed in the 40-patient registrational Phase 2 NEXICART-2 trial of CAR-T NXC-201, per prior guidance.
Immix Biopharma, Inc. today announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.